U.S. Markets open in 1 hr 5 mins

Ironwood Pharmaceuticals, Inc. (IRWD)


NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
18.31+0.18 (+0.99%)
At close: 4:00PM EDT
People also watch
INFIAEGRMNTASGYPRPTP
Full screen
Previous Close18.13
Open18.28
Bid14.19 x 100
Ask199,999.98 x 100
Day's Range17.87 - 18.39
52 Week Range12.18 - 19.94
Volume839,161
Avg. Volume1,262,312
Market Cap2.72B
Beta1.33
PE Ratio (TTM)-22.11
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Capital Cube3 days ago

    ETFs with exposure to Ironwood Pharmaceuticals, Inc. : June 26, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Ironwood Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to IRWD-US. Comparing the performance and risk of Ironwood Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Capital Cube13 days ago

    ETFs with exposure to Ironwood Pharmaceuticals, Inc. : June 16, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Ironwood Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to IRWD-US. Comparing the performance and risk of Ironwood Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Ironwood Pharmaceuticals, Inc. :IRWD-US: Earnings Analysis: Q1, 2017 By the Numbers : June 15, 2017
    Capital Cube14 days ago

    Ironwood Pharmaceuticals, Inc. :IRWD-US: Earnings Analysis: Q1, 2017 By the Numbers : June 15, 2017

    Categories: Yahoo FinanceGet free summary analysis Ironwood Pharmaceuticals, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Ironwood Pharmaceuticals, Inc. – Progenics Pharmaceuticals, Inc., Synergy Pharmaceuticals, Inc., Nektar Therapeutics, Astrazeneca PLC Sponsored ADR, Sucampo Pharmaceuticals, Inc. Class A, Cumberland Pharmaceuticals Inc. and Synthetic Biologics, Inc. ... Read more (Read more...)